Abstract 5225
Background
Chemotherapy-induced alopecia (CIA) is a common and distressing side effect of chemotherapy treatment. Significant progress has been made during the past 2 decades in treating many of the side effects associated with cancer chemotherapy including emesis, hematopoietic cytopenias, xerostomia, infection, pain, and thrombosis. Similar progress has not been made in the prevention of CIA, apart from scalp cooling. We set out to examine the uptake, patient satisfaction and efficacy (as perceived by medical staff and patients) of scalp cooling treatment among patients receiving chemotherapy.
Methods
We reviewed a prospectively maintained database of patients who were offered scalp cooling treatment in our oncology dayward between 01/10/2014 and 22/06/2018. We analysed patient uptake and efficacy as perceived and recorded by medical staff (“medical efficacy”). A questionnaire was sent to patients who had accepted scalp cooling treatment and were alive at follow-up, to assess patient perceived efficacy and patient satisfaction. Patient perceived efficacy was compared to medical efficacy using the Fisher’s exact test.
Results
The mean age was 60.1 (SD 10.9) and 91.4% of the patients were female. Uptake for scalp cooling was 49% (120/245). 75% (90/120) of patients were alive at follow up and 51% (46/90) responded to the questionnaire. Scalp cooling was considered efficacious in 63% (29/46) of patients, versus 43.3% (52/120) as assessed by the medical team, Fishers test p = 0.0253. 86.9% of patients who accepted scalp cooling and responded to the questionnaire (40/46) agreed or strongly agreed that they were satisfied with their choice to try scalp cooling, and 67.4% (31/46) agreed or strongly agreed that their experience of scalp cooling was a positive one. There was a strong association between patient perceived efficacy and satisfaction (p < 0.001).
Conclusions
The use of scalp cooling to prevent chemotherapy induced alopecia is an effective treatment in our real-world population. Patients were more likely than the medical team to consider scalp cooling treatment effective. We found high levels of patient satisfaction with the decision to try scalp cooling, even among patients whose treatment was ineffective.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract